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ABSTRACT
Results from randomised, controlled trials and routine clinical experience indicate that itraconazole can
be more effective than ﬂuconazole for prevention of invasive fungal infections in allogeneic stem-cell
transplant patients. The effective and safe use of prophylactic itraconazole requires an appreciation of
the drug’s pharmacokinetics, the optimal dosing regimen, and potential drug interactions. Because of
the erratic bioavailability of oral itraconazole capsules, only the intravenous (200 mg once-daily) and
oral cyclodextrin solution (200 mg twice-daily) formulations of the drug should be used. Prophylaxis
should be started after the completion of pre-transplant chemotherapy in order to avoid interactions
with chemotherapeutic agents. Patients unable to tolerate oral itraconazole should be given intravenous
itraconazole to maintain effective prophylaxis. Post-transplant interactions between itraconazole and
immunosuppressive agents or other drugs are generally not problematic, can be easily managed, and
need not limit the use of itraconazole. If these guidelines are followed, Aspergillus and other invasive
fungal infections can be safely prevented in allogeneic stem-cell transplant patients.
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INTRODUCTION
Invasive fungal infections are a common cause of
morbidity and mortality after allogeneic haemato-
poietic stem-cell transplantation [1]. At many
transplant centres, invasive fungal infections, espe-
cially those caused by Aspergillus species, are now
the leading cause of death from infection [2–5]. For
these reasons, antifungal prophylaxis is frequently
used in allogeneic stem-cell transplant recipients
[1,6]. Fluconazole or an amphotericin B formula-
tion have been the agents most commonly used.
Each of these agents, however, has signiﬁcant
limitations for prophylaxis. Fluconazole lacks reli-
able activity against Aspergillus species. Routine
use of prophylactic ﬂuconazole has been associated
with emergence of ﬂuconazole-resistant Candida
infections [7,8]. The amphotericin B formulations
are limited by toxicity and usually require intra-
venous administration. Lipid formulations of
amphotericin are very expensive. Furthermore,
the prophylactic efﬁcacy of both standard amph-
otericin B and the lipid formulations of amphoter-
icin has not been consistently demonstrated in
randomised, controlled trials [9–11].
Itraconazole is a wide-spectrum azole antifun-
gal agent that may overcome some of the limita-
tions of ﬂuconazole and amphotericin B as
prophylactic agents in allogeneic stem-cell trans-
plant patients. First, itraconazole is active against
Aspergillus species and some Candida species
resistant to ﬂuconazole [12]. Second, itraconazole
is less toxic than the amphotericin B formulations.
Third, itraconazole is now available in both an
intravenous formulation and an oral cyclodextrin
solution, which has much greater bioavailability
than the older itraconazole capsules [13,14]. Sev-
eral clinical trials have evaluated the intravenous
and oral cyclodextrin formulations of itraconazole
for antifungal prophylaxis in allogeneic stem-cell
transplant patients.
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US MULTICENTRE TRIAL OF
PROPHYLACTIC ITRACONAZOLE
The ﬁrst trial was a multicentre, randomised
trial performed at ﬁve transplant centres in the
USA [15]. Allogeneic stem-cell transplant recip-
ients were randomised to receive either itracon-
azole or ﬂuconazole, starting on day 1 after
transplantation and continuing until day 100
after transplantation. The itraconazole was ini-
tially given intravenously at a loading dose of
200 mg every 12 h for 2 days, and then 200 mg
was given intravenously every 24 h for 12 days.
Patients were then switched to oral itraconazole
solution at a dose of 200 mg every 12 h until
day 100 after transplantation. Fluconazole was
initially given intravenously at a dose of 400 mg
once-daily for 14 days and then orally at a dose
of 400 mg once-daily until day 100 after trans-
plantation. In both study groups, patients
unable to take or tolerate oral medications were
returned to the intravenous study drug. Neither
itraconazole nor ﬂuconazole was given before
transplantation during pre-transplant chemo-
therapy.
Proven invasive fungal infections occurred in
25% of the ﬂuconazole patients (17 of 67 patients)
compared to only 9% of the itraconazole patients
(six of 71 patients) during the ﬁrst 180 days after
transplantation (p ¼ 0.01). Itraconazole patients
had fewer infections due to both yeasts and
moulds. Candida glabrata and Candida krusei were
the most common yeasts causing infection, while
Aspergillus species were the most common
mould causing infection. The incidence of inva-
sive Aspergillus infection was 12% with ﬂuconaz-
ole but only 4% with itraconazole (p ¼ 0.12). The
higher incidence of invasive fungal infections in
the ﬂuconazole patients was associated with
greater resistance of fungal isolates to ﬂuconazole.
A previous concern about using itraconazole in
stem-cell transplant patients was the erratic bio-
availability of itraconazole capsules. However, in
this trial, the oral itraconazole solution as well as
the intravenous formulation of itraconazole were
used. Mean trough plasma itraconazole levels
greater than 600 ng ⁄mL were maintained with
both intravenous itraconazole and the oral itrac-
onazole solution throughout the study. A trough
plasma itraconazole level of more than
500 ng ⁄mL has been previously correlated with
effective prophylaxis [16].
Generally, except for more frequent gastroin-
testinal side-effects (usually nausea and vomiting)
with oral itraconazole solution, both itraconazole
and ﬂuconazole were well-tolerated. Thirteen
itraconazole patients received the intravenous
formulation of itraconazole for more than 30
consecutive days and tolerated the intravenous
drug well. Overall mortality during the study was
similar in both groups (42% with ﬂuconazole,
45% with itraconazole). However, fewer deaths
related to fungal infection occurred among itra-
conazole patients (9% vs. 18%, p ¼ 0.13).
ROUTINE USE OF PROPHYLACTIC
ITRACONAZOLE AT UNIVERSITY OF
CALIFORNIA LOS ANGELES (UCLA)
Based upon the favourable results with prophy-
lactic itraconazole in the US multicentre trial,
long-term itraconazole was introduced at the
University of Califonia, Los Angeles (UCLA) as
routine, standard antifungal prophylaxis in all
adult allogeneic stem-cell transplant patients in
December 2001 [17]. The protocol for itraconazole
antifungal prophylaxis at UCLA is summarised in
Table 1. From day 1 after transplantation to time
of engraftment, patients receive intravenous itrac-
onazole. The intravenous itraconazole is given at
a dose of 200 mg every 12 h for 2 days, followed
by 200 mg every 24 h. Itraconazole is not given
before transplantation during conditioning che-
motherapy, in order to avoid interactions between
itraconazole and chemotherapeutic agents that
Table 1. UCLA protocol for routine long-term itraconaz-
ole antifungal prophylaxis in allogeneic stem-cell trans-
plants [17]
Day +1 after transplant to time of engraftment
(ANC >500 ⁄mm3)
Intravenous itraconazole—200 mg intravenously every
12 h for 2 days; then 200 mg intravenously every 24 h
Do not give itraconazole before transplant during
conditioning chemotherapy, to avoid interactions
causing toxicity
From time of engraftment (ANC >500 ⁄mm3) to day +100
Oral itraconazole solution—200 mg orally evry 12 h
Return to intravenous itraconazole if patient is unable
to tolerate oral therapy (even as outpatient)
Do not substitute oral itraconazole capsules
After day +100
Continue oral itraconazole solution (200 mg orally every
12 h) in patients requiring corticosteroids for GVHD
ANC, Absolute Neutrophil Count.
GVHD, graft vs. host disease.
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can cause toxicity. From time of engraftment to
day 100 after transplantation, patients receive oral
itraconazole solution at a dose of 200 mg every
12 h. Patients unable to take oral therapy are
returned to intravenous itraconazole, even when
they are outpatients. We do not substitute oral
itraconazole capsules. Giving intravenous itracon-
azole at home is generally not a problem, since all
UCLA allogeneic transplant patients have a long-
term central intravenous catheter for the admin-
istration of blood products and medications (e.g.,
prophylactic ganciclovir) and the withdrawal of
blood for laboratory studies. Following day 100
after transplantation, oral itraconazole solution
(200 mg every 12 h) is continued in patients still
requiring corticosteroids for the prevention or
treatment of graft vs. host disease (GVHD).
From December 2001 to December 2003, 73
allogeneic stem-cell transplant patients received
itraconazole prophylaxis. These patients were at
high risk for Aspergillus infection (median age,
40 years; range, 18–64 years; advanced disease,
78%; previous autologous stem-cell transplant,
20%; unrelated donor, 41%; high-dose cortico-
steroids for prevention or treatment of GVHD,
86%; grade 2–4 GVHD, 45%). None of these 73
patients developed Aspergillus infection, which
is signiﬁcantly lower than the incidence of
Aspergillus infection in similar UCLA allogeneic
stem-cell transplant patients receiving ﬂuconazole
prophylaxis before 2001 (0% vs. 13%, p ¼ 0.004).
The only invasive fungal infections were three
cases of candidaemia (two itraconazole-sensitive,
and one itraconazole-resistant). There were no
deaths related to fungal infection. Except for
nausea and vomiting (19% incidence), itraconaz-
ole was well-tolerated. No cases of hepatotoxicity
or renal toxicity could be attributed to the itrac-
onazole. We do not ﬁnd it necessary to routinely
monitor serum itraconazole levels. Furthermore,
drug interactions involving itraconazole do not
limit its use and can easily be managed.
TRIAL OF PROPHYLACTIC
ITRACONAZOLE IN SEATTLE
A single-centre, randomised trial comparing itrac-
onazole with ﬂuconazole for antifungal prophy-
laxis in allogeneic stem-cell transplant patients
was performed by the Seattle transplant group
[18]. In this trial, both itraconazole and ﬂuconaz-
ole were started before transplantation, at the
beginning of conditioning chemotherapy, and
then continued to day 120 after transplantation,
or until discontinuation of corticosteroids for
GVHD, for a maximum of 180 days after trans-
plantation. Itraconazole was administered either
by intravenous infusion (200 mg once daily) or
orally in high doses (2.5 mg ⁄ kg of oral solution,
three times daily). Fluconazole was administered
at a dose of 400 mg once per day, intravenously or
orally. However, when a trend towards greater
hepatic toxicity was noted in patients receiving
itraconazole with a pre-transplant conditioning
regimen containing cyclophosphamide, the pro-
tocol was amended so that the study drugs were
started on the day of the stem-cell infusion (day 0)
rather than concurrently with conditioning ther-
apy [19]. After this amendment was made, there
were no signiﬁcant differences in liver toxicity
between itraconazole and ﬂuconazole patients.
Patients who could not tolerate the oral formula-
tions of the study drugs were usually eliminated
from the study trial rather than returned to the
intravenous study drug.
There were 151 patients available for evaluation
in the itraconazole group, and 148 patients avail-
able for evaluation in the ﬂuconazole group. The
overall incidence of invasive fungal infections
was 13% in the itraconazole group compared to
16% in the ﬂuconazole group. This was not a
signiﬁcant difference (p ¼ 0.46). However, break-
through invasive fungal infections, or infections
occurring while patients were actually taking the
study drug, were signiﬁcantly less frequent in the
itraconazole group (7% vs. 15%, p ¼ 0.03). This
reduction in breakthrough invasive fungal infec-
tions in the itraconazole group was due to a
reduction in Aspergillus mould infections (5% vs.
12%, p ¼ 0.03). There was no signiﬁcant differ-
ence in the incidence of candidaemia (2% with
itraconazole, 3% with ﬂuconazole).
The most common reason for discontinuation
of itraconazole during the trial was gastrointesti-
nal toxicity (usually nausea and vomiting), which
occurred in 24% of itraconazole patients and 5%
of ﬂuconazole patients (p <0.001). The reported
incidence of hepatotoxicity (tripling of baseline
total bilirubin) was extremely high in both study
groups (95% with itraconazole vs. 86% with
ﬂuconazole, p ¼ 0.02). Renal toxicity (doubling
of baseline serum creatinine) was reported in 7%
of itraconazole patients and in 3% of ﬂuconazole
patients (p ¼ 0.07). However, after the study
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protocol was amended so that the study drug was
administered only after completion of pre-trans-
plant chemotherapy, there were no signiﬁcant
differences in either hepatic toxicity or renal
toxicity between itraconazole patients and ﬂuco-
nazole patients.
Overall survival was similar in both groups of
patients (61% with itraconazole vs. 69% with
ﬂuconazole, p ¼ 0.11). Causes of death, including
death from fungal infection, did not differ.
COMPARISON OF US MULTICENTRE
AND SEATTLE TRIALS
A comparison of the US multicenter trial with the
Seattle trial is summarised in Table 2 and pro-
vides important insights into the most effective
way to use prophylactic itraconazole in allogeneic
stem-cell transplant recipients [15,18]. In the
Seattle trial, both prophylactic itraconazole and
ﬂuconazole were given to patients while they
were receiving pre-transplant chemotherapy. Ow-
ing to possible interactions between the itracon-
azole and chemotherapeutic drugs (especially
cyclophosphamide), patients who received itrac-
onazole developed higher serum bilirubin and
creatinine values during the ﬁrst 3 weeks after
transplantation [19]. In contrast, the US multicen-
ter trial, in which itraconazole and ﬂuconazole
were given only after conditioning therapy, found
no excess toxicity with itraconazole. After the
Seattle study protocol was amended to initiation
of itraconazole on day 0 of stem-cell infusion, no
signiﬁcant differences in hepatic or renal toxicity
were found between itraconazole and ﬂucona-
zole. The Seattle trial also used a relatively high
dose of oral itraconazole solution (2.5 mg ⁄ kg or
c. 200 mg three times daily), which was not well
tolerated by some patients because of frequent
nausea and vomiting. The US multicentre trial
used a lower dose of oral itraconazole solution
(200 mg twice daily), which was better tolerated
and still effective. Finally, patients in the Seattle
trial unable to tolerate the high dose of oral
itraconazole solution were usually eliminated
from the study and not returned to intravenous
itraconazole. Those patients in the US multicentre
trial and at UCLA who were unable to take oral
itraconazole solution were returned to intraven-
ous itraconazole. Thus, if prophylactic itraconaz-
ole is to be used effectively in stem-cell transplant
patients, the itraconazole should not be given
with pre-transplant conditioning chemotherapy,
oral itraconazole should be given at tolerable
doses (usually 200 mg twice daily), and patients
unable to take the oral drug should be given
intravenous itraconazole.
Both the US multicentre trial and the Seattle
trial found that itraconazole was superior to
ﬂuconazole for prevention of breakthrough inva-
sive fungal infections and Aspergillus mould
infections (Table 2). Systemic Candida infections
Table 2. Randomised trials of itraconazole vs. ﬂuconazole for antifungal prophylaxis in allogeneic stem-cell transplant
patients
US Multicentre Trial [15] Seattle Trial [18]




Itraconazole 200 mg twice daily 200 mg three times daily
Fluconazole 400 mg once daily 400 mg once daily
Patients returned to intravenous study drug Yes No
Incidence of invasive fungal infections
Overall incidence Lower with itraconazole Similar
Breakthrough infection Lower with itraconazole Lower with itraconazole
Mould infection Lower with itraconazole Lower with itraconazole
Candidiasis Lower with itraconazole Similar
Toxicity
Gastrointestinal intolerance Higher with itraconazole Higher with itraconazole
Hepatic Similar Higher with itraconazolea
Mortality
Overall Similar Similar
Fungal Lower with itraconazole Similar
aOnly when itraconazole is given with pre-transplant chemotherapy.
94 Clinical Microbiology and Infection, Volume 12 Supplement 7, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 7), 91–96
were also less frequent with prophylactic itracon-
azole in the US multicentre trial but not in the
Seattle trial.
Both trials reported a higher incidence of
gastrointestinal intolerance with prophylactic
itraconazole. Possible hepatotoxicity related to
the study drug was extremely high in the Seattle
trial (95% with itraconazole, 86% with ﬂuconaz-
ole). These incidences of hepatotoxicity are much
greater than those reported in other studies
[16,20–22] and suggest that factors other than
the itraconazole or ﬂuconazole were responsible
for the liver dysfunction in most of the patients.
Furthermore, greater hepatotoxicity with itracon-
azole was not observed in either the US multi-
centre trial or in the Seattle trial when
itraconazole was initiated after transplantation
instead of at the beginning of pre-transplant
conditioning therapy.
Overall mortality in the US multicentre trial
and in the Seattle trial was similar in both
itraconazole and ﬂuconazole patients. However,
in the US multicentre trial, in which fewer
patients discontinued the study drug, deaths
from invasive fungal infection were fewer among
patients given prophylactic itraconazole.
FUTURE CONSIDERATIONS
Several new antifungal agents have recently
become available for the treatment and preven-
tion of fungal infections. These agents include
voriconazole, posaconazole, caspofungin, mica-
fungin and anidulafungin [23]. Whether these
more expensive drugs can provide prophylactic
efﬁcacy similar to or better than that provided by
itraconazole requires additional investigation in
randomised, controlled trials. At the present,
prophylactic itraconazole, when administered at
a tolerable dose and initiated after the day of
transplantation (Table 1), is a safe and reliable
drug for the prevention of Aspergillus and other
serious invasive fungal infections in stem-cell
transplant recipients.
REFERENCES
1. Wingard JR. Fungal infections after bone marrow trans-
plant. Biol Blood Marrow Transplant 1999; 5: 55–68.
2. Van Burik JH, Leisenring W, Myerson D et al. The effect of
prophylactic ﬂuconazole on the clinical spectrum of fungal
diseases in bone marrow transplant recipients with special
attention to hepatic candidiasis. An autopsy study of 355
patients. Medicine (Baltimore) 1998; 77: 246–254.
3. Schmidt U, Pfaffenbach B, Quabeck K, Donhuijsen K.
Fungal infections after bone marrow transplantation—an
autopsy study. Mycoses 1991; 34 (suppl 1): 33–35.
4. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive
mold infections in allogeneic bone marrow transplant
recipients. Clin Infect Dis 2001; 32: 1319–1324.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epi-
demiology and outcome of mould infections in hemato-
poietic stem cell transplant recipients. Clin Infect Dis 2002;
34: 909–917.
6. Dykewicz CA. Summary of the guidelines for preventing
opportunistic infections among hematopoietic stem cell
transplant recipients. Clin Infect Dis 2001; 33: 139–144.
7. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE,
Saral R. Increase in Candida krusei infection among patients
with bone marrow transplantation and neutropenia trea-
ted prophylactically with ﬂuconazole. N Engl J Med 1991;
325: 1274–1277.
8. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE,
Saral R. Association of Torulopsis glabrata infections with
ﬂuconazole prophylaxis in neutropenic bone marrow
transplant patients. Antimicrob Agents Chemother 1993; 37:
1847–1849.
9. Wolf SN, Fay J, Stevens D et al. Fluconazole vs. low-dose
amphotericin B for the prevention of fungal infections in
patients undergoing bone marrow transplantation: a study
of the North American Marrow Transplant Group. Bone
Marrow Transplant 2000; 25: 853–859.
10. Tollemar J, Ringe´n O, Andersson S, Sundberg B, Ljungman
P, Tyden G. Randomized double-blind study of liposomal
amphotericin B (AmBisome) prophylaxis of invasive fun-
gal infections in bone marrow transplant recipients. Bone
Marrow Transplant 1993; 12: 577–582.
11. Kelsey SM, Goldman JM, McCann S et al. Liposomal
amphotericin (AmBisome) in the prophylaxis of fungal
infections in neutropenic patients: a randomised, double-
blind, placebo-controlled study. Bone Marrow Transplant
1999; 23: 163–168.
12. De Beule KL. Itraconazole: pharmacology, clinical experi-
ence, and future development. Int J Antimicrob Agents
Chemother 1996; 6: 175–181.
13. Boogaerts MA, Maertens J, Van Der Geest R et al. Phar-
macokinetics and safety of a 7-day administration of
intravenous itraconazole followed by a 14-day adminis-
tration of itraconazole oral solution in patients with
hematologic malignancy. Antimicrob Agents Chemother
2001; 45: 981–985.
14. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and
oral itraconazole versus intravenous amphotericin B
deoxycholate as empirical antifungal therapy for per-
sistent fever in neutropenic patients with cancer who are
receiving broad-spectrum antibacterial therapy. A rand-
omized, controlled trial. Ann Intern Med 2001; 135: 412–
422.
15. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intra-
venous and oral itraconazole versus intravenous and oral
ﬂuconazole for long-term antifungal prophylaxis in allo-
geneic hematopoietic stem-cell transplant recipients. A
multicenter, randomized trial. Ann Intern Med 2003; 138:
705–713.
Winston Itraconazole vs. ﬂuconazole prophylaxis 95
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 7), 91–96
16. Glasmacher A, Prentice A, Gorschlu¨ter M et al. Itraconaz-
ole prevents invasive fungal infections in neutropenic
patients treated for hematologic malignancies: evidence
from a meta-analysis of 3,597 patients. J Clin Oncol 2003;
21: 4615–4626.
17. Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ,
Paquette R, Territo MC. Elimination of Aspergillus infec-
tion in allogeneic stem cell transplant recipients with long-
term itraconazole prophylaxis: prevention is better than
treatment. Blood 2004; 104: 1581.
18. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus
ﬂuconazole for prevention of fungal infections in patients
receiving allogeneic stem cell transplants. Blood 2004; 103:
1527–1533.
19. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide
metabolism is affected by azole antifungals. Blood 2004;
103: 1557–1559.
20. Goodman JL, Winston DJ, Greenﬁeld RA et al. A con-
trolled trial of ﬂuconazole to prevent fungal infections in
patients undergoing bone marrow transplantation. N Engl
J Med 1992; 326: 845–851.
21. Slavin MA, Osborne B, Adams R et al. Efﬁcacy and safety
of ﬂuconazole prophylaxis for fungal infection after mar-
row transplantation—a prospective, randomized, double-
blind study. J Infect Dis 1995; 171: 1545–1552.
22. Winston DJ, Busuttil RW. Randomized controlled trial
of oral itraconazole solution versus intravenous ⁄ oral
ﬂuconazole for prevention of fungal infections in
liver transplant recipients. Transplantation 2002; 74: 688–
695.
23. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame´ S, Let-
scher-Bru V. Management of systemic fungal infections:
alternatives to itraconazole. J Antimicrob Chemother 2005; 56
(suppl 1): i39–i48.
96 Clinical Microbiology and Infection, Volume 12 Supplement 7, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 7), 91–96
